Demineralized Bone Matrix Market by Product, Administration Mode, Application, End-Use

Description

List of Tables

[186 Pages Report] The Demineralized Bone Matrix Market size was estimated at USD 671.14 million in 2023 and expected to reach USD 713.36 million in 2024, at a CAGR 6.54% to reach USD 1,046.37 million by 2030.

Demineralized bone matrix (DBM) is a type of bone graft material obtained from the collagen matrix of allogeneic bone, which has had its mineral content removed through an acid extraction process. This demineralization process exposes the bone's growth factors, particularly bone morphogenetic proteins (BMPs), making DBM osteoinductive and capable of promoting new bone formation. The primary factors contributing to the expansion of DBM use include its efficacy in bone repair and regeneration, its role as a graft extender in various orthopedic, dental, and spinal surgeries, and its potential to reduce the need for autografts, thus minimizing donor site morbidity. However, the variability in osteoinductive potential between different DBM products, the potential for immunogenic reaction, and the high costs associated with some DBM preparations pose significant challenges to their adoption. To address these restraints, ongoing research, and technological advancements focus on enhancing the consistency and osteoinductive potential of DBM products. Strategies include the development of composite grafts that combine DBM with synthetic or natural biomaterials to improve structural and functional properties and the application of advanced processing and sterilization techniques to preserve biological activity while ensuring safety. Expanding applications in emerging regions and integration with next-generation biologics signify dynamic growth avenues for the DBM, opening new doors for research, development, and clinical application.

KEY MARKET STATISTICS
Base Year [2023]	USD 671.14 million
Estimated Year [2024]	USD 713.36 million
Forecast Year [2030]	USD 1,046.37 million
CAGR (%)	6.54%

Product: Adoption of putty combined with cancellous chips form of DBM for extensive bone repair situations

DBM gel is a fluid-like formulation that allows for easy application in surgeries requiring precise bone graft placement, such as spinal fusion and certain dental applications. Its malleability makes it well-suited for minimally invasive procedures where space and precision are paramount. They are preferred in scenarios requiring minimal intervention and precise application without structural support. DBM putty offers a more malleable solution that can be applied to the surgical site and shaped as needed. Its versatility makes it widely used in a variety of bone repair procedures, including, but not limited to, spinal surgeries, fracture repair, and joint reconstruction. They are chosen for their versatility and ease of use in a broad range of surgical applications where both the delivery of growth factors and some degree of moldability are required. Putty combined with cancellous chips form combines DBM putty with cancellous bone chips, offering both osteoinductive and osteoconductive properties, making it an ideal choice for procedures requiring a scaffold for new bone growth, such as large bone defect repair and major reconstructive surgeries. They are preferred in extensive bone repair procedures where a blend of moldability, stability, and enhanced bone healing properties are needed.

Application: Exponential adoption of DBM for orthopedic surgical procedures

In spinal fusion surgery, a demineralized bone matrix (DBM) is utilized to promote the fusion of vertebrae. This application leverages the osteoinductive properties of DBM, which stimulate the body's natural bone-forming mechanisms. By aiding in the fusion process, DBM facilitates the stabilization of the spine, offering relief to patients with conditions such as degenerative disc disease, spondylolisthesis, and scoliosis. DBM finds significant applications in dental surgery, particularly in bone grafting procedures associated with dental implants and periodontal disease repair. It acts as a scaffold, supporting new bone growth in areas of deficiency, thus enhancing the stability and success rate of dental implants and aiding in the regeneration of bone lost to periodontal disease. Orthopedic surgery benefits from DBM in the treatment of bone defects and fractures. DBM's osteoconductive and osteoinductive characteristics are vital in scenarios where bone regeneration and repair are required. The use of DBM in joint reconstruction surgeries, particularly in hip and knee replacements, enhances the integration of the prosthetic components with the host bone. It is applied around the prosthetic components to promote bone ingrowth, thereby securing the implant and improving its long-term stability. In craniomaxillofacial procedures, DBM is used to repair bone defects resulting from trauma, congenital conditions, or resections. Its ability to support bone formation makes it an integral part of reconstructive surgeries in this complex anatomical region, contributing to both functional and aesthetic outcomes.

Regional Insights

In the Americas, particularly the United States, the use of DBM is highly regulated but widely accepted, driven by an advanced healthcare infrastructure and a high incidence of bone-related disorders. Production in this region is characterized by stringent FDA regulations, ensuring product safety and efficacy. Major companies are backed by robust R&D investments and expansive distribution networks. The APAC market, while rapidly growing, presents a contrast with a diverse regulatory landscape and a high need stemming from increasing orthopedic surgeries. Local manufacturers are emerging, leveraging cost advantages and regional customization of DBM products. The EMEA market, with its diverse regulatory environment across countries, shows a balanced blend of advanced healthcare systems in European countries and emerging markets in the Middle East and Africa. The region is marked by a strong presence of both global DBM players and local entities adapting to regional healthcare needs and compliance standards. They are working on including DBM with their comprehensive bone graft portfolio, enabling its wider commercialization.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Demineralized Bone Matrix Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Demineralized Bone Matrix Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Demineralized Bone Matrix Market, highlighting leading vendors and their innovative profiles. These include Advanced Biotech Products P Ltd, AlloSource, Arthrex, Inc., Bioventus LLC, Cerapedics.Inc., Curasan AG, Exactech, Inc., Geistlich Pharma AG, Globus Medical, HansBioMed., Institut Straumann AG, Integra LifeSciences Holdings Corporation, Johnson & Johnson Services, Inc., KLS Martin SE & Co. KG, Kuros Biosciences Ltd., Medtronic PLC, NovaBone by Halma PLC, Orthofix Medical Inc., Osteogenics Biomedical, RTI Surgical Holdings, Inc., SpineWave, Inc., Stryker Corporation, Synerheal, XTANT Medical, and Zimmer Biomet.

Market Segmentation & Coverage

This research report categorizes the Demineralized Bone Matrix Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Gel
- Putty
- Putty Combined with Cancellous Chips

Administration Mode
- Implantation
- Injection

Application
- Craniomaxillofacial Surgeries
- Dental Reconstructions
- Joint Reconstruction
- Orthopedic Repairs
- Spinal Fusion Surgery

End-Use
- Hospitals
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Demineralized Bone Matrix Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Demineralized Bone Matrix Market?

3. What are the technology trends and regulatory frameworks in the Demineralized Bone Matrix Market?

4. What is the market share of the leading vendors in the Demineralized Bone Matrix Market?

5. Which modes and strategic moves are suitable for entering the Demineralized Bone Matrix Market?

Product Code: MRR-F97DD5A7D66F

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of bone injuries and adoption of orthopedic surgeries
  - 5.1.1.2. Government investments promoting orthopedic research activities
- 5.1.2. Restraints
  - 5.1.2.1. High cost and reimbursement limitations of demineralized bone matrix
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in the demineralized bone matrix materials
  - 5.1.3.2. Collaboration between stakeholders for supply of demineralized bone matrix
- 5.1.4. Challenges
  - 5.1.4.1. Quality and consistency concerns of demineralized bone matrix
5.2. Market Segmentation Analysis
- 5.2.1. Product: Adoption of putty combined with cancellous chips form of DBM for extensive bone repair situations
- 5.2.2. Application: Exponential adoption of DBM for orthopedic surgical procedures
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Demineralized Bone Matrix Market, by Product

6.1. Introduction
6.2. Gel
6.3. Putty
6.4. Putty Combined with Cancellous Chips

7. Demineralized Bone Matrix Market, by Administration Mode

7.1. Introduction
7.2. Implantation
7.3. Injection

8. Demineralized Bone Matrix Market, by Application

8.1. Introduction
8.2. Craniomaxillofacial Surgeries
8.3. Dental Reconstructions
8.4. Joint Reconstruction
8.5. Orthopedic Repairs
8.6. Spinal Fusion Surgery

9. Demineralized Bone Matrix Market, by End-Use

9.1. Introduction
9.2. Hospitals
9.3. Specialty Clinics

10. Americas Demineralized Bone Matrix Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Demineralized Bone Matrix Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Demineralized Bone Matrix Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Paragon 28 Launches BEAST Cortical Fibers Expanding its Biologics Portfolio
- 13.3.2. Biogennix Launches OsteoSPAN Fiber Matrix
- 13.3.3. Geistlich Announces The Dramatic Expansion Of Their Allograft Portfolio
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio